VIP152 is a selective CDK9 inhibitor with pre-clinical in vitro and in vivo efficacy in chronic lymphocytic leukemia

Chronic lymphocytic leukemia (CLL) is effectively treated with targeted therapies including Bruton tyrosine kinase inhibitors and BCL2 antagonists. When these become ineffective, treatment options are limited. Positive transcription elongation factor complex (P-TEFb), a heterodimeric protein complex...

Descripción completa

Detalles Bibliográficos
Autores principales: Sher, Steven, Whipp, Ethan, Walker, Janek, Zhang, Pu, Beaver, Larry, Williams, Katie, Orwick, Shelley, Ravikrishnan, Janani, Walker, Brandi, Perry, Elizabeth, Gregory, Charles, Purcell, Matthew, Pan, Alexander, Yan, Pearlly, Alinari, Lapo, Johnson, Amy J., Frigault, Melanie M., Greer, Joy M., Hamdy, Ahmed, Izumi, Raquel, Mo, Xiaokui, Sampath, Deepa, Woyach, Jennifer, Blachly, James, Byrd, John C., Lapalombella, Rosa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9898036/
https://www.ncbi.nlm.nih.gov/pubmed/36376377
http://dx.doi.org/10.1038/s41375-022-01758-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9898036/
https://www.ncbi.nlm.nih.gov/pubmed/36376377
http://dx.doi.org/10.1038/s41375-022-01758-z

Ejemplares similares